TB/HIV Coinfection
"Modelling the Economic Benefits of Tuberculosis Preventive Therapy for People with HIV: The Example of Zambia."
Published in TB and Outbreaks Week, July 28th, 1997
According to the authors' abstract of an article published in AIDS, "Objective: To assess the economic benefits and costs of providing isoniazid preventive therapy for tuberculosis (TB) in HIV-infected persons in Zambia. Design: A spreadsheet model incorporating variables drawn from published studies and unpublished data. Subjects: Data drawn from a number of different studies and published literature involving a range of subjects. Setting: Zambia. Results: Using data primarily from Zambia we have modelled the costs and benefits of a TB preventive therapy programme using daily isoniazid for 6 months. The base-case scenario assumes...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Epidemiology (TB)
Supplemental Fingerprinting Improves Epidemiologic Investigation - Cytokine Gene Therapy
Adenoviral-Mediated IFN Administration Enhances Bacterial Clearance - Environment (Water Contamination)
Mycobacteria Common in Bottled Water in Greece - Genetics (TB)
IS6110 Present in Non-Tuberculosis Mycobacteria - Genotyping
(GTG)5 is Epidemiological Tool for Nontuberculous Mycobacteria - Industry News (Joint Venture)
Collaboration on Antibacterial Protease Inhibitors Announced - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
